Pharmacy & Biological SciencesCategory
All eyes were on Oklahoma last week, when the first case in a flood of litigation against opioid drug manufacturers began Tuesday.
Headlines proclaimed a potential game changer in treating cardiovascular disease—Vascepa—and company shares quickly soared, but the study behind the claim remains a mystery.
On October 24th, President Trump signed a package of bills designed to confront and combat the nation’s opioid epidemic. On November 2nd, the FDA approved Dsuvia.
The proposal would have Medicare base what it pays for some expensive drugs on the average prices in other industrialized countries.
The new drug, Xofluza, is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years.
Of the fifty most influential people innovating healthcare named by Time Magazine, those with ties to biopharma make up a large percentage.
The Trump administration proposed a new rule this week which demands drug makers disclose list prices for medications in their TV commercials.
A spike in cases of children with a rare neurological disease that causes polio-like symptoms has health officials scrambling to understand the illness.
Of the roughly $23.3 billion in sales growth seen by 45 top pharmaceutical products, $14.3 billion of that has been tied to price increases, not demand.
Drug companies typically have less than 10 years of exclusive rights once a drug hits the marketplace. They can extend their monopolies by layering in secondary patents.